ABSTRACT BACKGROUND Beta-blocker therapy after acute myocardial infarction (MI) improves survival. Beta-blocker doses used
Although the guidelines do not refer to specific beta-blockers or doses, basic evidence-based medicine principles support the use of betablockers that have been studied in trials at the doses used or targeted; trials that report dosing indicate that the majority of patients achieved target doses. However, doses of clinically used beta-blocker are substantially lower (8, 9) . The impact of this large-scale underdosing of beta-blockers on the beneficial effects of beta-blocker therapy is unknown. Analyses of post-MI beta-blocker trials have related mortality reduction to heart rate reduction (10, 11) ; because heart rate reduction is dose dependent, this supports the notion that there could be a dose-dependent reduction in mortality. The OBTAIN (Outcomes of Betablocker Therapy After Myocardial Infarction) study is an observational multicenter registry in which beta-blocker dosing information was collected in all patients with acute MI at participating centers to assess the effect of dose on survival. The OBTAIN hypothesis was that higher dose beta-blocker therapy is associated with increased survival.
METHODS
STUDY DESIGN AND OVERSIGHT. Initiated in 2007, OBTAIN was a companion registry to the PACE-MI (PACEmaker and ß-Blocker Therapy Post-Myocardial Infarction) trial (12) . Detailed information on betablocker dosing was collected in the registry. There were 26 participating centers in the United States and 1 in Canada. When the trial was terminated in 2009, it was noted that beta-blocker utilization was nearly universal, but that most patients were treated with doses #25% of the target doses used in clinical trials. At that time, the decision was made to continue the registry and evaluate vital status for at least 2 years to test the hypothesis that there is a dose-response relationship in the beneficial effect of beta-blocker therapy on survival. After protocol modification to include vital status assessment and resubmission for institutional review board approval, 21 of the original sites continued their participation (including 92% of the registry patients). An additional 5 U.S. sites were recruited.
The study was funded by the National Heart, Lung, and Blood Institute, and an observational study monitoring board, appointed by the institute, monitored study conduct. The study was approved by each site's institutional review board with a waiver of consent for registry enrollment. Participating centers and study committees and personnel are listed in the Online Appendix.
PATIENTS. Consecutive patients admitted with acute MI at participating sites were entered into the registry. Acute MI was diagnosed by: 1) either creatine kinase elevation >2 times or troponin elevation >3 times the upper limit of normal; and 2) either chest pain (or equivalent symptoms suggestive of MI) or electrocardiographic changes consistent with MI.
Basic demographic, historical, and hospitalization information, as well as information regarding the index MI, was collected. Discharge beta-blocker type and dose were recorded. All data were collected at the site, and deidentified patient information was entered in a Web-based electronic data capture system.
BETA-BLOCKER DOSING. Beta-blocker type and dose were chosen by the managing physician. For the purposes of the present study, target doses for the most commonly used beta-blockers were as follows: metoprolol 200 mg/day (13, 14) ; carvedilol 50 mg/day (19) . On the basis of the dose administered, a proportion of the target dose was calculated (administered/target dose) only for patients taking 1 of these beta-blockers. Beta-blocker doses were divided into 5 by comparing Kaplan-Meier survival curves with a log-rank test. Cox proportional hazards regression was used to test for the independent effects of beta-blocker dosing on survival. The following pre-specified patient characteristics were used in multivariable adjustment: age, sex, white race, Hispanic ethnicity, cardiac enzymes, left ventricular ejection fraction, diabetes, hypertension, hypercholesterolemia, ST-segment elevation MI, thrombolytic therapy, primary percutaneous coronary intervention, length of stay, and other discharge medications (aspirin, angiotensin-converting enzyme [ACE] inhibitors/angiotensin receptor blockers, and statins).
A pre-specified secondary analysis was performed comparing the outcomes for low-dose (#25%) and high-dose ($50%) beta-blocker therapy.
Further sensitivity analyses of the effect of the 4 beta-blocker doses on outcome included evaluation of 3-year outcomes. Multivariable analysis included an expanded set of all covariates listed in Table 1 , including use of carvedilol versus metoprolol. Random effects (shared frailty model) were also included for each of the recruiting hospitals to better model differences in mortality among them. Quadratic and cubic polynomial terms for continuous predictors were included to account for potential nonlinearity.
Propensity score analysis was also performed as an alternative adjustment for patient differences in the 4 beta-blocker dose groups. To calculate the propensity score, we used mixed effects linear regression with random effects of the recruiting centers, continuous discharge beta-blocker dose (percentage of target dose) as a dependent variable, and the expanded control variable set reported in Table 1 (includinguadratic and cubic polynomial terms for continuous   predictors) . Thus, the propensity scores represent the predicted discharge beta-blocker dose, given the extended set of patient characteristics. The propensity score was used as a control variable in the proportional hazards frailty regression model.
Further details are provided in the Online Appendix.
All tests were 2-tailed, and a conventional 5% significance level was used. A gatekeeper hypothesis strategy for type I error control was used for prespecified study endpoints; alpha levels were to be adjusted for subsequent tests if the gatekeeper null hypothesis was rejected. Analyses were performed by using SAS version 9.4 (SAS Institute, Inc., Cary, North Carolina).
RESULTS
The registry included 7,057 patients. In-hospital mortality was 4.7%, and 43 patients were lost to follow-up. 20.2% were taking the same, a higher, or a lower dose, respectively, with a 3.8% discontinuation rate and a 3.4% initiation rate in patients not discharged on beta-blockers. From discharge to 1 year, of the patients treated with >12.5% to 25% of the target dose, only 4% were subsequently in the >50% of the target dose group. Of the patients treated with >50% of the target dose, only 12% were subsequently treated with #25% of the target dose. In this cohort, beta-blocker therapy was associated with an unadjusted 51% (adjusted 45%; 95% confidence interval [CI]: 33% to 55%) lower mortality compared with no beta-blocker therapy. Table 4) . After the pre-specified multivariable adjustment, relative to the >50% target dose, mortality did not differ for the >0% to 12.5% and >25% to 50% doses, and was borderline statistically significant in those taking >12.5% to 25% of the target dose but not after multivariable adjustment with the extended set of covariates. Table 2) . Goldberger et al.
Beta-Blockers After MI S E P T E M B E R 2 9 , 2 0 1 5 : 1 4 3 1 -4 1 Table 3 presents the multivariable HRs with extended follow-up to 3 years (using the pre-specified multivariable analysis) and the analyses focusing on the 4 beta-blocker dose groups using multivariable analysis with the expanded set of covariates (Table 5) and the propensity score analysis. Relative to the >50% dose group, there were no significant differences between the >0% to 12.5% and >25% to 50% dose groups. Although there were lower HRs in the >12.5% to 25% dose group, these findings were not consistently significant across all analyses. Because the >12.5% to 25% group was the largest and experienced the lowest mortality, the HRs relative to the >12.5% to 25% dose group were analyzed ( Figure 1 ). 12.5%, >12.5% to 25%, and >25% to 50% doses.
DISCUSSION
The present study was designed to evaluate whether higher dose beta-blocker therapy is associated with increased survival compared with lower doses in patients discharged from the hospital after MI. Contrary to our hypothesis, improved outcome with higher dose beta-blocker therapy (specifically the target beta-blocker doses used in previous randomized clinical trials) was not observed. Although baseline differences in the treatment groups preclude a definitive determination of the dose-response relationship between beta-blocker dose and mortality post-MI, the lowest observed mortality was at 25% of the target dose (i.e., metoprolol 50 mg/day).
However, there was no consistent statistically significant reduction in mortality with this dose with the various analyses used to adjust for baseline differences among the groups. In relation to these Kaplan-Meier survival curves for (A) the primary (unadjusted) analysis comparing the 5 discharge doses (no beta-blocker and >0% to 12.5%, >12.5% to 25%, >25% to 50%, and >50% of the target dose) of beta-blockers and (B) the secondary (unadjusted) analysis comparing low-dose (#25% of the target dose) versus high-dose ($50% of the target dose) beta-blocker therapy. BB ¼ beta-blocker; MI ¼ myocardial infarction.
Goldberger et al. Because the trial hypothesis was that higher doses would be associated with improved outcomes, an a priori noninferiority analysis was not proposed to show noninferiority of the >12.5% to 25% target dose.
Although it would not be appropriate to conduct noninferiority testing with a margin determined in a post-hoc manner, our post-hoc calculations showed that the noninferiority margin which would change the conclusion regarding noninferiority of the >12.5%
to 25% target dose would have to be relatively small.
Further studies will need to determine whether fixed target dosing for all post-MI patients or individualized dosing on the basis of patient or MI characteristics will optimize outcomes. Table 2 . Predictors were: 1) the 5 pre-specified dose groups (none, >0% to 12.5%, >12.5% to 25%, >25% to 50%, and >50% of the target dose); and 2) the low-dose (#25% of target dose) and high-dose ($50% of the target dose) groups. HRs for continuous variables are associated with 1 unit increase in the measure. Tables 1 and 2 . Adjusted hazard ratios for 3-year survival with multivariable analysis incorporating the prespecified variable set, multivariable analysis incorporating the expanded variable set, and propensity score analysis comparing mortality with each beta-blocker dose versus the mortality observed in the >12.5% to 25% of the target dose group. *p < 0.03. †p < 0.001.
Abbreviations as in
suggest that beta-adrenergic receptor polymorphisms influence outcomes in acute coronary syndromes and heart failure (35) (36) (37) (38) , but the dose-response effect is unknown. Furthermore, genetic polymorphisms may affect beta-blocker metabolism and concentration (39, 40) . A number of analyses have suggested that mortality reduction post-MI is related more to the degree of heart rate reduction than to the type of beta-blocker (10, 11) . Whether these factors can allow for optimal titration of beta-blocker dose for an individual post-MI patient requires further study.
There are several reasons for the current high rate of low-dose beta-blocker therapy post-MI. This may represent either physician or patient inertia. Some patients may not be able to tolerate higher doses for hemodynamic reasons or due to noncardiac adverse effects or a more severe medical condition. Finally, advanced conduction system or myocardial disease may also preclude dose up-titration. There is no a priori reason for these factors to bias toward greater benefit with lower doses.
STUDY LIMITATIONS. An important caveat for the current findings is that they do not represent randomized clinical trial results. As such, multiple betablockers were used, and the doses were indexed to doses used in clinical trials. Although this method does not assure equivalent effects, it should be noted that 93% of the treated patients in this registry received either metoprolol or carvedilol, which was accounted for in the sensitivity analyses. In addition, the survival analysis was indexed to the discharge beta-blocker dose. Although dose changes do occur over time, only a minority of patients had their doses up-titrated. Being a registry, there was also nonuniform distribution of risk factors among groups. In addition, the specific rationale for the individual dosing regimens is unknown. Thus, the multivariable/propensity score analyses may have incompletely adjusted for these differences, and there may be unmeasured covariates, such as the extent of coronary artery disease or follow-up heart rate and blood pressure, which could affect the findings.
However, multivariable adjustment and propensity score analyses consistently showed no greater benefit with full-dose beta-blocker therapy, contrary to the original hypothesis. Thus, despite these limitations, it is apparent that there is a need to stimulate further randomized trials of post-MI beta-blocker therapy from their currently dormant state. Goldberger et al.
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